Payment overview · 2025
General Payments
$930.75
50 reported records · 17 companies
Healthcare provider profile · identity verified
Eric A Duffield, P.A
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LANSING, MI · NPI 1245427004
Verified facts
What the public records show
CMS Open Payments records show Eric A Duffield, P.A received $930.75 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.00 | 26.9% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.51 | 11.0% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $94.93 | 10.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.68 | 9.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.84 | 7.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.06 | 5.1% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $43.08 | 4.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $38.72 | 4.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.31 | 3.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $25.44 | 2.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.94 | 2.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.87 | 2.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.06 | 2.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.63 | 2.0% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $18.24 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.14 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.30 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $930.75 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $122.75 | 9 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $94.93 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.85 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.85 | 4 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $74.02 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.84 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.98 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.06 | 3 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $46.60 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $35.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 33 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 58 |
| Omeprazole | Omeprazole | 196 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 164 | 52 |
| Montelukast Sodium | Montelukast Sodium | 144 | 40 |
| Losartan Potassium | Losartan Potassium | 140 | 36 |
| Lisinopril | Lisinopril | 131 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 25 |
| Gabapentin | Gabapentin | 109 | 24 |
| Metformin Hcl | Metformin Hcl | 106 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 33 |
| Potassium Chloride | Potassium Chloride | 94 | 26 |
| Furosemide | Furosemide | 81 | 22 |
| Simvastatin | Simvastatin | 81 | 23 |
| Carvedilol | Carvedilol | 74 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 16 |
| Prednisone | Prednisone | 70 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 17 |
| Trazodone Hcl | Trazodone Hcl | 60 | 17 |
| Eliquis | Apixaban | 54 | 14 |
| Allopurinol | Allopurinol | 50 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Alprazolam | Alprazolam | 49 | 15 |
| Sertraline Hcl | Sertraline Hcl | 49 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 12 |
| Famotidine | Famotidine | 41 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 14 |
| Roflumilast | Roflumilast | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 12 |
| Fluconazole | Fluconazole | 33 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 15 |
| Ozempic | Semaglutide | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Nystatin | Nystatin | 27 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 14 |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $930.75 · 50 records | ABBVIE INC. | AREXVY, Arikayce, Auvelity, Bimzelx, CAPLYTA, DUPIXENT, GLASSIA, Hillrom - Vest System Model 105 Home Care, INNOVAMATRIX AC, JASCAYD, JOURNAVX, MOUNJARO, OFEV, Ozempic, Prolastin-C Liquid, QULIPTA, RINVOQ, Rybelsus, SKYRIZI, SMARTVEST, TRELEGY ELLIPTA, TREMFYA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error